Operating Income (Loss) in USD of RVL Pharmaceuticals plc from Q3 2017 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
RVL Pharmaceuticals plc quarterly/annual Operating Income (Loss) history and change rate from Q3 2017 to Q2 2023.
  • RVL Pharmaceuticals plc Operating Income (Loss) for the quarter ending 30 Jun 2023 was -$22M, a 45.6% decline year-over-year.
  • RVL Pharmaceuticals plc Operating Income (Loss) for the twelve months ending 30 Jun 2023 was -$70.8M, a 1.36% decline year-over-year.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2022 was -$59M, a 28.7% increase from 2021.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2021 was -$82.8M, a 8.71% increase from 2020.
  • RVL Pharmaceuticals plc annual Operating Income (Loss) for 2020 was -$90.7M, a 29% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

RVL Pharmaceuticals plc Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$70.8M -$22M -$6.9M -45.6% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 -$63.9M -$10.3M -$4.9M -90.7% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q4 2022 -$59M -$24.5M -$404K -1.67% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2023
Q3 2022 -$58.6M -$13.9M +$11.2M +44.7% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022
Q2 2022 -$69.8M -$15.1M +$5.05M +25% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$74.9M -$5.4M +$7.87M +59.3% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$82.8M -$24.1M +$51.8M +68.2% 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2023
Q3 2021 -$135M -$25.2M -$26.6M -1864% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$108M -$20.2M -$2.86M -16.5% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 -$105M -$13.3M -$14.5M -1210% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 -$90.7M -$76M -$206M -158% 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2022
Q3 2020 $116M $1.43M +$124M 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$8.63M -$17.3M +$114M +86.9% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 -$123M $1.2M +$4.69M 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021
Q4 2019 -$128M $130M +$238M 01 Oct 2019 31 Dec 2019 8-K 08 Sep 2021
Q3 2019 -$366M -$123M -$120M -4629% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$245M -$132M -$144M -1142% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020
Q1 2019 -$101M -$3.5M -$2.4M -219% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020
Q4 2018 -$98.5M -$107M 01 Oct 2018 31 Dec 2018 10-K 19 Mar 2020
Q3 2018 -$2.6M +$15.6M +85.7% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019
Q2 2018 $12.6M 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 -$1.1M 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q3 2017 -$18.2M 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018

RVL Pharmaceuticals plc Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$59M +$23.8M +28.7% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2023
2021 -$82.8M +$7.9M +8.71% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023
2020 -$90.7M +$37.1M +29% 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022
2019 -$128M -$29.2M -29.7% 01 Jan 2019 31 Dec 2019 8-K 08 Sep 2021
2018 -$98.5M -$46.5M -89.2% 01 Jan 2018 31 Dec 2018 10-K 19 Mar 2020
2017 -$52.1M 01 Jan 2017 31 Dec 2017 8-K 20 Dec 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.